SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

l	OMB Number:	3235-0287
l	OMB Number: Estimated average but hours per response:	rden
l	hours per response:	0.5

			01.36		invesu	nem c	ompany Act o	511940					
1. Name and Addre	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS,							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
SCHLEIFER	<u>LEONARD S</u>			<u>C.</u> [REGN]				01120	<u>-</u> ,	Х	Director	10% (Dwner
		Middle)								Х	Officer (give title below)	Other below	(specify
(Last) 777 OLD SAW	(First) (MILL RIVER ROA	3. Date of Earliest Transaction (Month/Day/Year) 04/05/2022							President & CEO				
(Street)			4. lf /	Amendment, Date	of Orig	inal Fi	led (Month/Da	ay/Year)		. Indiv ine)	idual or Joint/Grou	p Filing (Check	Applicable
TARRYTOWN	NY	10591								X	Form filed by One	e Reporting Per	son
(City)	(State) (Zip)									Form filed by Mo Person	re than One Re	porting
	Table	e I - Non-Deriva	tive	Securities Ac	quire	d, Di	sposed of	f, or B	Benefic	ially	Owned		
1. Title of Security (Instr. 3)		2. Transactio Date (Month/Day/Y	Execution Date,		3. Transaction Code (Instr. 8)							6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)		

		Code	V	Amount	(D)	Price	(Instr. 3 and 4)		
Common Stock	04/05/2022	S ⁽¹⁾		4,461	D	\$710.05 ⁽²⁾	13,831	Ι	By Trust
Common Stock	04/06/2022	S ⁽¹⁾		2,653	D	\$710.04 ⁽³⁾	11,178	Ι	By Trust
Common Stock							465,922	D	
Common Stock							200,000	Ι	2021 GRAT
Common Stock							5,874	Ι	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispe of (D	r osed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	nd 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

2. Represents volume-weighted average price of sales of 4,461 shares of Company stock on April 5, 2022 at prices ranging from \$710.00 to \$710.22. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 5, 2022 at each separate price.

3. Represents volume-weighted average price of sales of 2,653 shares of Company stock on April 6, 2022 at prices ranging from \$710.00 to \$710.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 6, 2022 at each separate price.

> /s/**Leonard S. Schleifer 04/07/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.